Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: A case study with brentuximab-vedotin

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 39, Issue 6, 2012, Pages 643-659

  Shah, Dhaval K ^a   Haddish Berhane, Nahor ^a   Betts, Alison ^a  

^a PFIZER INC   (United States)

Author keywords

Antibody drug conjugate; Brentuximab vedotin; Clinical translation; Mechanistic mathematical model; Pharmacokinetics pharmacodynamics; SGN 35

Indexed keywords

BRENTUXIMAB VEDOTIN;

ARTICLE; CANCER INHIBITION; CANCER PATIENT; CANCER SURVIVAL; CASE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DISPOSITION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MULTIPLE CYCLE TREATMENT; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOCONJUGATES; MICE; MODELS, BIOLOGICAL; NEOPLASMS; TRANSLATIONAL MEDICAL RESEARCH; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84880733804     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-012-9276-y     Document Type: Article

References (37)

1. Webb S (2011) Pharma interest surges in antibody drug conjugates. Nat Biotechnol 29(4):297-298
2. Ducry L, Stump B (2010) Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem 21(1):5-13
3. Zhou Q, Gallo JM (2011) The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic. AAPS J 13(1):111-120
4. Younes A, Yasothan U, Kirkpatrick P (2012) Brentuximab-vedotin. Nat Rev Drug Discov 11(1):19-20
5. Sanderson RJ, Hering MA, James SF, Sun MM, Doronina SO, Siadak AW, Senter PD, Wahl AF (2005) In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res 11(2 Pt 1):843-852 (Pubitemid 40116913)
6. Agoram BM, van der Graaf PH (2012) Biomarkers and biomeasures: key enablers for pharmacokinetic-pharmacodynamic modeling in drug discovery and development. Bioanalysis 4(10):1143-1145
7. Haddish-Berhane N, Shah DK, Betts A, Ma D, DiJoseph J, Leal M, Sapra P, Hans-Peter G (2012) A PK/PD modeling and simulation approach to predict clinical efficacy of antibody drug conjugates from mouse xenograft data. J Pharmacokinet Pharmacodyn (manuscript in preparation)
8. Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, Senter PD, Alley SC (2010) Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 16(3):888-897
9. Alley SC (2010) Antibody-Auristatin conjugates for cancer: antibody and drug pharmacokinetics and disposition. Paper presented at the AAPS national biotechnology conference, San Francisco, 16 May 2010-19 May 2010
10. Schmidt MM, Wittrup KD (2009) A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 8(10):2861-2871
11. Thurber GM, Schmidt MM, Wittrup KD (2008) Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 60(12):1421-1434
12. Thurber GM, Schmidt MM, Wittrup KD (2008) Factors determining antibody distribution in tumors. Trends Pharmacol Sci 29(2):57-61
13. Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, Kissler KM, Bernhardt SX, Kopcha AK, Zabinski RF, Meyer DL, Francisco JA (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 10(20):7063-7070 (Pubitemid 39383058)
14. Alley S, Kissler K, Morris-Tilden C, Miyamoto J, Senter P, Benjamin D (2007) Effective tumor targeting by auristatin antibody-drug conjugates. AACR meeting abstracts (annual-meeting):# 4088. AACR, Philadelphia
15. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, Law CL, Doronina SO, Siegall CB, Senter PD, Wahl AF (2003) cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102(4):1458-1465 (Pubitemid 36988057)
16. Senter P (2009) Prospects and challenges for antibody targeting: antibody-drug conjugates (ADCs). Paper presented at the European federation for pharmaceutical sciences presentation, Stockholm
17. Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, Germani M, Poggesi I, Rocchetti M (2004) Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 64(3):1094-1101 (Pubitemid 38176915)
18. Yang J, Mager DE, Straubinger RM (2010) Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems. AAPS J 12(1):1-10
19. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A (2010) Brentuximab-vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363(19):1812-1821
20. Bartlett NL, Forero-Torres A, Rosenblatt JD, Fanale M, Horning SJ, Thompson S, Sievers EL, Kennedy DA (2009) Complete remissions with SGN-35 weekly dosing: a phase 1 dose-escalation study in relapsed/refractory HL or systemic ALCL patients. Paper presented at the ASCO annual meeting, Orlando, 29 May 2009-6 June 2009
21. Fromm JR, McEarchern JA, Kennedy D, T. A, Shustov AR, Gopal AK (2010: # 1789) Preclinical and clinical binding properties, internalization kinetics, and clinicopathological activity of brentuximab-vedotin (SGN-35): a novel antibody drug conjugate for anaplastic large cell lymphoma and classical Hodgkin lymphoma. Paper presented at the American society of hematology 2010 annual meeting, Orlando, 12 April 2010-12 July 2010
22. Brons PP, Raemaekers JM, Bogman MJ, van Erp PE, Boezeman JB, Pennings AH, Wessels HM, Haanen C (1992) Cell cycle kinetics in malignant lymphoma studied with in vivo iododeoxyuridine administration, nuclear Ki-67 staining, and flow cytometry. Blood 80(9):2336-2343
23. Zhao Y, Kosorok MR, Zeng D (2009) Reinforcement learning design for cancer clinical trials. Stat Med 28(26):3294-3315
24. Fanale MA, Forero-Torres A, Rosenblatt JD, Advani RH, Franklin AR, Kennedy DA, Han TH, Sievers EL, Bartlett NL (2012) A phase I weekly dosing study of brentuximab-vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res 18(1):248-255
25. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579-586 (Pubitemid 350002966)
26. D'Argenio DZ, Schumitzky A (1979) A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 9(2):115-134 (Pubitemid 9104986)
27. Arrowsmith J (2011) Trial watch: phase II failures: 2008-2010. Nat Rev Drug Discov 10(5):328-329
28. Berry DA (2011) Adaptive clinical trials in oncology. Nat Rev Clin Oncol 9(4):199-207
29. Begley CG, Ellis LM (2012) Drug development: raise standards for preclinical cancer research. Nature 483:531-533
30. Ternant D, Henin E, Cartron G, Tod M, Paintaud G, Girard P (2009) Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma. Br J Clin Pharmacol 68(4):561-573
31. Lobo ED, Balthasar JP (2002) Pharmacodynamic modeling of chemotherapeutic effects: application of a transit compartment model to characterize methotrexate effects in vitro. AAPS Pharm Sci 4(4):E42
32. Jumbe NL, Xin Y, Leipold DD, Crocker L, Dugger D, Mai E, Sliwkowski MX, Fielder PJ, Tibbitts J (2010) Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. J Pharmacokinet Pharmacodyn 37(3):221-242
33. Morgan P, Van Der Graaf PH, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, Street SD (2012) Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival. Drug Discov Today 17(9-10):419-424
34. Krippendorff BF, Oyarzun DA, Huisinga W (2012) Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modelling. J Pharmacokinet Pharmacodyn 39(2):125-139
35. Wang X, Ma D, Olson WC, Heston WD (2011) In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen. Mol Cancer Ther 10(9):1728-1739
36. Nagata S, Onda M, Numata Y, Santora K, Beers R, Kreitman RJ, Pastan I (2002) Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments. Clin Cancer Res 8(7):2345-2355 (Pubitemid 34753609)
37. Sutherland MS, Sanderson RJ, Gordon KA, Andreyka J, Cerveny CG, Yu C, Lewis TS, Meyer DL, Zabinski RF, Doronina SO, Senter PD, Law CL, Wahl AF (2006) Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem 281(15):10540-10547 (Pubitemid 43864594)